Danna Chan, PharmD, MS

Associate Director, Clinical Pharmacology
Taiho Oncology, Inc.

Poster(s):

• (T-021) Semi-physiological population pharmacokinetic (PPK) model using dose optimization data for ASTX030, an oral fixed-dose combination (FDC) of CDA inhibitor cedazuridine and azacitidine in MDS patients
  Tuesday, November 12, 2024

  7:00 AM – 5:00 PM MST